MedTrace Logo

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

NCT07536815 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-27

No results posted yet for this study

Summary

This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.

Conditions

  • TNBC
  • TNBC - Triple-Negative Breast Cancer
  • TNBC, Triple Negative Breast Cancer

Interventions

DRUG

leronlimab (PRO 140)

Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Sponsors & Collaborators

  • WEP Clinical

    collaborator UNKNOWN

  • CytoDyn, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07536815 on ClinicalTrials.gov